GILEAD SCIENCES, INC. 4

Gilead Sciences CFO Andrew D. Dickinson sold 3,000 shares of GILD common stock for about $415,000 under a Rule 10b5-1 plan.

On August 17, 2026, Gilead Sciences, Inc. Chief Financial Officer Andrew D. Dickinson sold 3,000 shares of Gilead common stock at an average price of $138.36 per share, for total proceeds of approximately $415,080. The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024, indicating a scheduled diversification rather than a discretionary trade. Following this transaction, Dickinson beneficially owns 165,646 shares of Gilead common stock in direct form, which, based on the reported sale price, represents an equity stake valued at roughly $22.9 million.

Filing Facts

CIK

882095

Ticker

GILD

Form

4

Source Type

fda

Accession

0001310204-26-000024

Alert Tier

8